FDA Approves Javadin (clonidine hydrochloride) Oral Solution for the Treatment of Hypertension
Woburn, MA - October 24, 2025 -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin (clonidine hydrochloride) oral solution, the only F
FDA Approves Contepo (fosfomycin) for Injection for the Treatment of Complicated Urinary Tract Infections
October 22, 2025 -- The U.S. Food and Drug Administration (FDA) has approved Contepo (fosfomycin) for injection for the treatment of patients 18 years of age and older with complicated urinary tract i
FDA Approves Epioxa (riboflavin 5’-phosphate) Ophthalmic Solution for the Treatment of Keratoconus
Aliso Viejo, CA – October 20, 2025 -- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
FDA Approves Ferabright (ferumoxytol injection) Contrast Agent for Magnetic Resonance Imaging of the Brain
Woburn, MA — October 17, 2025 -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Ferabright (ferumoxytol injection), the first and only iron
FDA Approves Jascayd (nerandomilast) to Treat Idiopathic Pulmonary Fibrosis
October 9, 2025 -- Boehringer Ingelheim’s Jascayd (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) as an oral treatment option for idiopathic pulmonary fibrosis
FDA Approves Lasix ONYU (furosemide) for Treatment of Edema in Heart Failure
Burlington, Massachusetts, October 8, 2025 – SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix ONYU (furosemide inject
FDA Approves Eydenzelt (aflibercept-boav), a Biosimilar to Eylea
INCHEON, South Korea, Oct. 9, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eydenzelt (aflibercept-boav), biosimilar referencing Ey
FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria
EAST HANOVER, N.J., Sept. 30, 2025 -- Novartis announced today that Rhapsido (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic
FDA Approves Enoby (denosumab-qbde), a Biosimilar to Prolia
Budapest, Hungary and London, UK, 29 September 2025 -- Gedeon Richter Plc. (“Richter”) and Hikma Pharmaceuticals Plc. along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (“Hikma”) an
FDA Approves Xtrenbo (denosumab- qbde), a Biosimilar to Xgeva
Budapest, Hungary and London, UK, 29 September 2025 -- Gedeon Richter Plc. (“Richter”) and Hikma Pharmaceuticals Plc. along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (“Hikma”) an
FDA Approves Qivigy (immune globulin intravenous, human-kthm) for Primary Humoral Immunodeficiency
September 29, 2025 -- Kedrion Biopharma announced today that it has received FDA approval for Qivigy®, a new 10% Immunoglobulin for intravenous use, indicated for treatment of adults with Primary humo
FDA Approves Clotic (clotrimazole otic solution), First Treatment with Clinical Evidence for Fungal Ear Infections
September 2025: Madrid, Spain, 26 September 2025 -- Laboratorios Salvat, S.A. ("Salvat") announced today that the U.S. Food and Drug Administration (FDA) has approved Clotic (clotrimazole ot
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism
